Executive Summary

Antiretroviral therapy has become a mature platform for viral suppression and prevention, but its application to longevity is still an investigational question. The most credible longevity hypothesis does not treat all antiretrovirals as interchangeable. It focuses on whether selected nucleoside or nucleotide reverse transcriptase inhibitors can suppress retroelement-linked inflammation and shift measurable biology of aging.

For professional readers, the strategic distinction is between HIV longevity and gerotherapeutic repurposing. HIV longevity is already a clinical reality created by sustained viral suppression and better chronic disease management. Gerotherapeutic repurposing is a newer research frontier that requires placebo-controlled trials, validated aging endpoints, direct retrotransposon readouts, and careful safety selection before it can support clinical or regulatory claims.

Where ART Stands in 2026

The standard ART center of gravity in 2026 remains integrase strand transfer inhibitor (INSTI)-based oral therapy. The U.S. Department of Health and Human Services (DHHS) Panel recommends initial regimens for most people with HIV based on an oral second-generation INSTI plus two nucleoside reverse transcriptase inhibitors (NRTIs), specifically bictegravir with tenofovir alafenamide and emtricitabine, or dolutegravir plus tenofovir alafenamide and emtricitabine, tenofovir disoproxil fumarate and emtricitabine, or tenofovir disoproxil fumarate and lamivudine; dolutegravir and lamivudine can be used in some people with HIV. 1

WHO's January 2026 clinical management update confirms the global preference for dolutegravir-based regimens for initial and subsequent HIV treatment, recommends darunavir with ritonavir when a protease inhibitor is needed, and supports selected use of long-acting injectable ART and oral two-drug simplification in clinically stable individuals. That alignment matters because longevity strategy begins with reliable suppression, tolerability, adherence, and regimen durability, not with speculative anti-aging biology. 2

Long-Acting Therapy Changes the Operating Model

The treatment field has shifted from a simple daily-tablet paradigm to a portfolio that includes long-acting maintenance and long-acting prevention. CABENUVA (cabotegravir plus rilpivirine) is labeled as a complete regimen for HIV-1 treatment in adults and adolescents who are virologically suppressed with HIV-1 RNA below 50 copies per mL on a stable antiretroviral regimen, have no history of treatment failure, and have no known or suspected resistance to cabotegravir or rilpivirine; the label includes every-two-month continuation dosing after initiation. 3

Lenacapavir occupies two different roles. SUNLECA is labeled as a capsid inhibitor used with other antiretrovirals for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are failing their current regimen because of resistance, intolerance, or safety considerations; YEZTUGO is labeled for HIV-1 PrEP in at-risk adults and adolescents weighing at least 35 kg, with initiation dosing followed by continuation injection dosing once every six months. 45

The long-acting shift improves the design space for adherence, stigma reduction, and clinical delivery, but it also changes the risk model. YEZTUGO carries a boxed warning on drug resistance risk when used for PrEP in undiagnosed HIV-1 infection and requires HIV-1 testing before initiation and each subsequent injection; CABENUVA labeling addresses missed injections, residual drug concentrations, and the need to maintain suppressive coverage when injections are delayed. 53

HIV Longevity Is Now a Healthspan Problem

Longevity for people with HIV is no longer defined only by avoidance of AIDS-related mortality. NIH guidance states that effective ART has increased survival and produced a growing older HIV population; in U.S. 2022 data cited by the guidance, 38% of people with HIV were aged at least 55 years and 13.2% were aged at least 65 years, while the life-expectancy difference versus the general population has narrowed to an estimated five years or fewer for those with CD4 counts above 500 cells per microliter after starting ART. 6

The remaining burden is healthspan. NIH guidance identifies immunologic aging and systemic inflammation as contributors to comorbidities across organ systems and to frailty phenotypes, notes that people with HIV have about a twofold higher risk of atherosclerotic cardiovascular disease and develop incident ASCVD about a decade earlier, and recommends close attention to polypharmacy, renal, liver, metabolic, cardiovascular, cognitive, and bone health in older people with HIV. 6

The practical implication is that ART selection in older adults is a geriatric pharmacology problem as much as an antiviral problem. Regimen optimization may be needed to reduce toxicities, drug-drug interactions, or pill burden; NIH guidance specifically highlights comorbidities such as kidney disease, elevated cardiovascular risk, and osteoporosis when selecting regimens, and notes that NRTI dose adjustment may be necessary in reduced renal function. 6

Why Reverse Transcriptase Inhibition Entered Geroscience

The biological bridge between antiretrovirals and geroscience is not HIV suppression per se. It is the observation that aging is associated with loss of epigenetic repression of retrotransposons, particularly LINE-1 elements, and that reverse-transcribed retroelement products can activate innate immune pathways linked to sterile inflammation. A 2019 Nature study reported that LINE-1 elements become derepressed during cellular senescence, activate a type I interferon response, and that lamivudine downregulated interferon activation and age-associated inflammation in aged mice. 7

The drug-class specificity matters. A PLOS ONE study using an in vitro LINE-1 retrotransposition reporter assay found that nucleoside or nucleotide reverse transcriptase inhibitors including stavudine, zidovudine, tenofovir disoproxil fumarate, and lamivudine inhibited human LINE-1 retrotransposition to varying degrees, while the non-nucleoside reverse transcriptase inhibitor nevirapine did not show the same effect. 8

A 2023 review framed NRTIs as candidate geroprotectors through several proposed mechanisms, including repression of LINE-1 elements, effects on mitochondrial translation and ATF-4 signaling, and inhibition of P2X7-mediated inflammasome activation. That breadth is scientifically interesting, but it also creates translational complexity because beneficial stress-response signaling, mitochondrial toxicity, renal and bone considerations, and indication-specific risk tolerance must all be separated rather than averaged into a class-wide claim. 96

The 2026 FTC/TAF Aging Signal

The most direct human signal now comes from a 2026 medRxiv preprint archived in PubMed Central that evaluated DNA methylation-based biological aging measures in healthy adults without HIV, aged 18 to 50 years, using samples from two randomized, directly observed dosing pharmacokinetic studies of FDA-approved nucleoside or nucleotide reverse transcriptase inhibitor regimens for 12 weeks. One analysis evaluated emtricitabine plus tenofovir alafenamide (FTC/TAF), in 36 participants. The other evaluated emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF), in 43 participants. 10

In that post hoc analysis, FTC/TAF was associated with decreases in DNA methylation aging measures including DunedinPACE by -0.061 (with p=0.019) and PhenoAge by -6.33 (with p=0.008); DNA methylation proxies of inflammatory biomarkers also declined, including epigenetic interleukin-6, abbreviated IL-6, by -0.058 (with p=0.029) and a trend toward lower C-reactive protein (with p=0.059). The FTC/TDF study did not show significant changes across epigenetic clocks and proxies in the abstracted findings. 10

This signal should be read as hypothesis-strengthening, not practice-changing. The source is explicitly a preprint and not yet peer reviewed, the analysis was post hoc, the regimens were evaluated in separate pharmacokinetic studies rather than a single placebo-controlled geroscience trial, and the authors call for prospective placebo-controlled studies integrating clinical pharmacology, direct transposable element readouts, and prespecified geroscience and DNA methylation aging endpoints. 10

Neuroinflammation and Claims-Based Signals

A separate but relevant thread is neuroinflammation. A 2025 Alzheimer's & Dementia analysis reported that NRTI exposure was associated with significantly lower Alzheimer disease incidence in two large U.S. health insurance databases, while exposure to non-NRTIs, protease inhibitors, and integrase strand transfer inhibitors was not associated with reduced Alzheimer disease incidence. 11

This finding reinforces the mechanistic argument that NRTI biology may have effects outside HIV replication, but it remains observational. The authors used claims databases, propensity score matching, time-dependent Cox models, and other bias-mitigation steps, yet still stated that prospective randomized clinical trials are needed to establish causality. 11

The Evidence Boundary

The most important analytical mistake would be to describe antiretroviral therapy as an anti-aging class. ART includes integrase inhibitors, NRTIs, NNRTIs, protease inhibitors, capsid inhibitors, entry inhibitors, and other agents with different pharmacology; the longevity hypothesis is concentrated around specific reverse transcriptase inhibitor mechanisms and, based on the 2026 preprint, may be sensitive to prodrug and intracellular exposure differences between TAF and TDF. 1089

Safety cannot be treated as a secondary issue because the target population for longevity applications could include people without HIV and without immediate infectious disease risk. NIH guidance for older people with HIV already emphasizes renal, liver, cardiovascular, central nervous system, metabolic, and bone monitoring, and the FDA labels for long-acting agents show that even successful antiretroviral platforms carry regimen-specific requirements around resistance, drug interactions, missed dosing, residual drug exposure, and route-specific adverse events. 6354

The near-term translational path is therefore not broad off-label longevity use. It is a structured development program that selects a candidate regimen or molecule, defines the biology to be modified, specifies whether the target is LINE-1 reverse transcription, inflammasome activation, or another pathway, and prospectively links pharmacokinetics to direct mechanistic biomarkers, epigenetic measures, functional endpoints, and safety stopping rules. 1079

Translation and Regulatory Implications

For developers, the most credible regulatory strategy would avoid a claim that a marketed HIV regimen slows aging. A more defensible path would begin with a nonclinical and clinical pharmacology package showing target engagement, then move into proof-of-mechanism trials with prespecified biomarkers, followed by studies that connect biomarker movement to functional or disease-relevant outcomes. The 2026 preprint itself identifies the need for prospective placebo-controlled studies with direct transposable element readouts and prespecified geroscience and DNA methylation endpoints. 10

For clinicians and payers, the immediate relevance is narrower. In people with HIV, ART optimization already functions as longevity medicine because it preserves viral suppression while minimizing drug toxicity, interactions, adherence burden, and comorbidity amplification. In people without HIV, the risk-benefit threshold is different because prevention or geroscience use exposes otherwise uninfected individuals to antiretroviral pharmacology, resistance-management obligations, and monitoring requirements. 651

For researchers, the critical comparison is no longer ART versus no ART. It is TAF-like intracellular exposure versus TDF-like exposure, NRTI versus non-NRTI activity, reverse transcriptase-dependent versus inflammasome-dependent mechanisms, and epigenetic biomarker response versus durable clinical benefit. Without those separations, the field risks converting an interesting mechanistic signal into an overbroad therapeutic narrative. 108119

Conclusion

In 2026, antiretroviral therapy has two longevity stories. The established story is clinical: durable HIV suppression, simpler regimens, long-acting options, and better management of comorbidities are allowing more people with HIV to live longer, with the next challenge centered on healthspan. The emerging story is biological: selected NRTIs may modify retroelement-linked inflammation and DNA methylation measures of aging, with early human signals now visible but not yet definitive.

The field should proceed with discipline. The opportunity is real enough to justify prospective trials, but not mature enough to justify broad anti-aging claims. The next step is to turn mechanism into evidence architecture: define the target, measure target engagement, select the right population, prespecify aging endpoints, and prove that biomarker changes predict outcomes that matter.